Evidence map›Paper›PMID 34413148›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022

PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma.

Andrea C Lo, Lyndon P James, Anca Prica, Adam Raymakers, Stuart Peacock, Melody Qu, Alex V Louie, Kerry J Savage, Laurie H Sehn, David Hodgson and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Prognostic value of interimAnnals of hematology · 2023
    Article
  3. Duodenal-type follicular lymphoma inAmerican journal of nuclear medicine and molecular imaging · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 5 countries.

Andrea C LoDepartment of Radiation Oncology, BC Cancer, University of British Columbia, Vancouver, British Columbia, Canada; andrea.lo@bccancer.bc.ca.
Lyndon P JamesPhD Program in Health Policy, Harvard University, Cambridge, Massachusetts.
Anca PricaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Adam RaymakersCancer Control Research, BC Cancer, Vancouver, British Columbia, Canada.
Stuart PeacockCancer Control Research, BC Cancer, Vancouver, British Columbia, Canada.
Melody QuDepartment of Radiation Oncology, London Health Sciences Centre, Western University, London, Ontario, Canada.
Alex V LouieDepartment of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Kerry J SavageCentre for Lymphoid Cancer, Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada.
Laurie H SehnCentre for Lymphoid Cancer, Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada.
David HodgsonRadiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Joanna C YangDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, California.
Hans T T EichDepartment of Radiation Oncology, University Hospital Muenster, Muenster, Germany.
Andrew WirthDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; and.
M G Myriam HuninkCenter for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
BC Cancer Agency · CAPrincess Margaret Cancer Centre · CAErasmus University Rotterdam · NLHarvard University · USHealth Sciences Centre · CALondon Health Sciences Centre · CAPeter MacCallum Cancer Centre · AUUniversity Hospital Münster · DEUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective was to assess the cost-effectiveness of staging PET/CT in early-stage follicular lymphoma (FL) from the Canadian health-care system perspective.

Indexed as

Lymphoma, FollicularPositron Emission Tomography Computed TomographyCanadaCost-Benefit AnalysisHumansQuality-Adjusted Life Yearscost-effectiveness analysisfollicular lymphomaPET/CTradiation therapystaging

Identifiers

PMID34413148
PMCPMC8973292
OpenAlexW3193558506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.